Giovanni Grignani
0000-0001-5515-569X
Publication & Citation Trends
Publications
632 total
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Cited by 0
Semantic Scholar
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.
Cited by 0
Semantic Scholar
Long-term outcomes after discontinuation of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) in the POD1UM-201 trial.
Cited by 0
Semantic Scholar
Correction: Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation
Cited by 0
Semantic Scholar
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group.
Cited by 2
Semantic Scholar
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW‐1): A Randomized, Open‐Label, Phase 3, Non‐Inferiority Trial OA
Cited by 1
Semantic Scholar
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes
Cited by 0
Semantic Scholar
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Cited by 4
Semantic Scholar
Research Topics
Sarcoma Diagnosis and Treatment
(297)
CAR-T cell therapy research
(102)
Vascular Tumors and Angiosarcomas
(82)
Gastrointestinal Tumor Research and Treatment
(76)
Cardiac tumors and thrombi
(71)
Affiliations
Université Claude Bernard Lyon 1
Eurac Research
Memorial Sloan Kettering Cancer Center
American Red Cross
GTx (United States)